[
  {
    "ts": null,
    "headline": "Why Major Pharmaceutical Stocks Tumbled on Tuesday",
    "summary": "Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons.  The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.  Major stocks in the sector took notable hits, including but not at all limited to Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Eli Lilly (NYSE: LLY).",
    "url": "https://finnhub.io/api/news?id=2bd069c65381560c2ef32dbe3b2c794993fd96b8069833579bc89ea53d6e9dee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743548979,
      "headline": "Why Major Pharmaceutical Stocks Tumbled on Tuesday",
      "id": 133658292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons.  The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.  Major stocks in the sector took notable hits, including but not at all limited to Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Eli Lilly (NYSE: LLY).",
      "url": "https://finnhub.io/api/news?id=2bd069c65381560c2ef32dbe3b2c794993fd96b8069833579bc89ea53d6e9dee"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip",
    "summary": "Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include younger adults, and announced a collaboration with Flagship Pioneering for autoimmune therapeutics. Despite this positive news, Pfizer's share price declined by 3% last week, aligning somewhat with the broader market's 3.4% drop amid heightened investor anxiety over impending U.S. tariffs. While rotation into big tech buoyed by Tesla's gains contrasted the broader downturn,...",
    "url": "https://finnhub.io/api/news?id=d27e280e1892201f0977cb66c682d149fb57c316305fde2930087a75148da82b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743528873,
      "headline": "Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip",
      "id": 133655238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include younger adults, and announced a collaboration with Flagship Pioneering for autoimmune therapeutics. Despite this positive news, Pfizer's share price declined by 3% last week, aligning somewhat with the broader market's 3.4% drop amid heightened investor anxiety over impending U.S. tariffs. While rotation into big tech buoyed by Tesla's gains contrasted the broader downturn,...",
      "url": "https://finnhub.io/api/news?id=d27e280e1892201f0977cb66c682d149fb57c316305fde2930087a75148da82b"
    }
  },
  {
    "ts": null,
    "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=9fc9a406d2d57b24ba58f5f610c0c12bdc0d4463edcbe8d535f1bded5865034e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743523813,
      "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
      "id": 133655239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=9fc9a406d2d57b24ba58f5f610c0c12bdc0d4463edcbe8d535f1bded5865034e"
    }
  },
  {
    "ts": null,
    "headline": "The FDA Is ‘Finished’ as Firings Sweep Health Agencies. Drug Stocks Are Falling.",
    "summary": "The FDA Is ‘Finished’ as Firings Sweep Health Agencies. Drug Stocks Are Falling.",
    "url": "https://finnhub.io/api/news?id=a97bb8bb4dd81521a6a0c69985f3f112753146db38962c05a885622fbfb743fd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743516120,
      "headline": "The FDA Is ‘Finished’ as Firings Sweep Health Agencies. Drug Stocks Are Falling.",
      "id": 134147661,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "The FDA Is ‘Finished’ as Firings Sweep Health Agencies. Drug Stocks Are Falling.",
      "url": "https://finnhub.io/api/news?id=a97bb8bb4dd81521a6a0c69985f3f112753146db38962c05a885622fbfb743fd"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts?",
    "summary": "We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in […]",
    "url": "https://finnhub.io/api/news?id=64a152cb5055491107912f118431bb628e9a4ce5ed53a13d6a2bba585bac1828",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743516093,
      "headline": "Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts?",
      "id": 133645409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in […]",
      "url": "https://finnhub.io/api/news?id=64a152cb5055491107912f118431bb628e9a4ce5ed53a13d6a2bba585bac1828"
    }
  },
  {
    "ts": null,
    "headline": "Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release",
    "summary": "Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate CORT stock a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=368ce757e01a565768f88857b827cbe28f3355251bce805f5a40f96b5055ef85",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743514989,
      "headline": "Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release",
      "id": 133653037,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194013376/image_2194013376.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate CORT stock a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=368ce757e01a565768f88857b827cbe28f3355251bce805f5a40f96b5055ef85"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSK",
    "summary": "Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV.",
    "url": "https://finnhub.io/api/news?id=88b17334813e0eeac1a5f510ac7a20373dbe6249a8d022dd079750702808c592",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743507060,
      "headline": "Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSK",
      "id": 133645410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV.",
      "url": "https://finnhub.io/api/news?id=88b17334813e0eeac1a5f510ac7a20373dbe6249a8d022dd079750702808c592"
    }
  },
  {
    "ts": null,
    "headline": "3 Ultra-High-Yield Dividend Stocks to Buy in April",
    "summary": "March winds bring April showers.  Seriously, there are several great ultra-high-yield dividend stocks to buy in April.  Ares Capital (NASDAQ: ARCC) offers such a high dividend yield, at 8.68%, that you might wonder if it's sustainable.",
    "url": "https://finnhub.io/api/news?id=846c9f12b4a4cd1c10b98309392495da9ed6d3846c9b346bb95371a0f0b57376",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743501000,
      "headline": "3 Ultra-High-Yield Dividend Stocks to Buy in April",
      "id": 133645412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "March winds bring April showers.  Seriously, there are several great ultra-high-yield dividend stocks to buy in April.  Ares Capital (NASDAQ: ARCC) offers such a high dividend yield, at 8.68%, that you might wonder if it's sustainable.",
      "url": "https://finnhub.io/api/news?id=846c9f12b4a4cd1c10b98309392495da9ed6d3846c9b346bb95371a0f0b57376"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: extension of indication for RSV vaccine",
    "summary": "Pfizer announced on Tuesday that the European Commission has approved its bivalent respiratory syncytial virus vaccine for the immunization of adults.The vaccine, previously indicated for patients...",
    "url": "https://finnhub.io/api/news?id=50a5d79a6399dcc5fc07099d4af04676a4ad6c585299f265024e8a4215f9e049",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743496594,
      "headline": "Pfizer: extension of indication for RSV vaccine",
      "id": 133634904,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer announced on Tuesday that the European Commission has approved its bivalent respiratory syncytial virus vaccine for the immunization of adults.The vaccine, previously indicated for patients...",
      "url": "https://finnhub.io/api/news?id=50a5d79a6399dcc5fc07099d4af04676a4ad6c585299f265024e8a4215f9e049"
    }
  },
  {
    "ts": null,
    "headline": "Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’",
    "summary": "Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.",
    "url": "https://finnhub.io/api/news?id=83e237d0d3f1568ee1053d60e67de18749653987cf3e352c6cfbe9799334b130",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743494400,
      "headline": "Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’",
      "id": 133645414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.",
      "url": "https://finnhub.io/api/news?id=83e237d0d3f1568ee1053d60e67de18749653987cf3e352c6cfbe9799334b130"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease",
    "summary": "NEW YORK, April 01, 2025--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now of",
    "url": "https://finnhub.io/api/news?id=615fb97121f09356f35387e83ca592fb1e3b5d5066fe4901fab4292b1613795c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743490800,
      "headline": "European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease",
      "id": 133633066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, April 01, 2025--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now of",
      "url": "https://finnhub.io/api/news?id=615fb97121f09356f35387e83ca592fb1e3b5d5066fe4901fab4292b1613795c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Gets Expanded European Approval of Abrysvo RSV Vaccine for All Adults",
    "summary": "By Colin Kellaher Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday...",
    "url": "https://finnhub.io/api/news?id=9ac0063ad0c36f9dace8beaf83afab0c9afb06b376106449995ec4fa1c4971a4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743488170,
      "headline": "Pfizer Gets Expanded European Approval of Abrysvo RSV Vaccine for All Adults",
      "id": 133633982,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday...",
      "url": "https://finnhub.io/api/news?id=9ac0063ad0c36f9dace8beaf83afab0c9afb06b376106449995ec4fa1c4971a4"
    }
  }
]